$0 is the total value of KLP Enterprises, LLC's 1 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 200.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | CONFIDENTIAL0 | $0 | – | 0 | +100.0% | 0.00% | – | |
| Exit | GELESIS HLDGS INC | $0 | – | -12,056,626 | -100.0% | -100.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Andrew D. Wingate #1
- Lucinda Falk #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONFIDENTIAL | 24 | Q2 2023 | 0.0% |
| Celldex Therapeutics, Inc. | 9 | Q4 2018 | 100.0% |
| HYATT | 2 | Q4 2013 | 100.0% |
| GELESIS HLDGS INC | 1 | Q1 2023 | 100.0% |
View KLP Enterprises, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Celldex Therapeutics, Inc. | December 09, 2016 | 6,865,006 | 5.7% |
View KLP Enterprises, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-15 |
| 13F-HR | 2023-08-15 |
| 13F-HR | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-01 |
| 13F-NT | 2022-05-09 |
| 13F-NT | 2022-02-08 |
| 3 | 2022-01-21 |
View KLP Enterprises, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.